How many clinical-trial readouts are scheduled for September 2027?

pdufa.bio currently tracks 33 clinical-trial readouts with dates in September 2027, each linked to a primary source. The list updates as new filings appear and dates shift.

What is a clinical-trial readout date?

A readout date is the estimated time a trial reports topline results, based on its registered primary-completion date; these are estimates and shift.

Does pdufa.bio predict whether these will be approved?

No. We do not publish per-drug approval probabilities. We provide the verified facts, primary-source links, and historical base rates so you can judge for yourself.

pdufa.bio

Calendar Readouts Devices Decisions Approvals/yr Trial odds Learn Research Methodology

Home › Readouts › September 2027

September 2027 clinical-trial readouts

trial-readout estimates for September 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.

← August 2027 October 2027 →

33 readouts

ALKS · Sep 2027 (est.)

Olz/Sam — Bipolar I Disorder

BHVN · Sep 2027 (est.)

BHV-1300 — Graves Disease

CHRS · Sep 2027 (est.)

CHS-1420 — Hepatocellular Carcinoma

CLYM · Sep 2027 (est.)

Budoprutug — Systemic Lupus Erthematosus

CORT · Sep 2027 (est.)

Relacorilant — Adenocarcinoma

CSTL · Sep 2027 (est.)

FCX-007 — Dystrophic Epidermolysis Bullosa

CYTK · Sep 2027 (est.)

Omecamtiv Mecarbil — Heart Failure

DFTX · Sep 2027 (est.)

DT120 — Major Depressive Disorder

HUMA · Sep 2027 (est.)

Human Acellular Vessel — Trauma

IMVT · Sep 2027 (est.)

IMVT-1402 — Rheumatoid Arthritis

IOVA · Sep 2027 (est.)

Lifileucel plus Pembrolizumab — Unresectable Melanoma

KARD · Sep 2027 (est.)

danicamtiv — Symptomatic Genetic Dilated Cardiomyopathy

KTTA · Sep 2027 (est.)

PAS-004 — NF1 Mutation

KYTX · Sep 2027 (est.)

Standard of Care Treatment — Myasthenia Gravis

NEO · Sep 2027 (est.)

IO102-IO103 in combination with pembrolizumab — Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

RZLT · Sep 2027 (est.)

Ersodetug — Tumor Hyperinsulinism (Tumor HI)

SMMT · Sep 2027 (est.)

Ivonescimab — Metastatic Esophageal Adenocarcinoma

TLSI · Sep 2027 (est.)

Pembrolizumab — Locally Advanced Pancreatic Adenocarcinoma

UPB · Sep 2027 (est.)

Verekitug — Severe Asthma

XFOR · Sep 2027 (est.)

Mavorixafor — Neutropenia

AGEN · Sep 2027 (est.)

Botensilimab — Metastatic Colorectal Cancer

ARWR · Sep 2027 (est.)

Plozasiran — Obesity

INCY · Sep 2027 (est.)

Corticosteroids — Chronic Graft-versus-host-disease

ACXP · Sep 2027 (est.)

Ibezapolstat — Clostridium Difficile Infection Recurrence

ADPT · Sep 2027 (est.)

Bendamustine — Lymphoma

VIR · Sep 2027 (est.)

VIR-5500 — Hormone-refractory Prostate Cancer

CNTA · Sep 2027 (est.)

cleminorexton — Narcolepsy Type 1

FATE · Sep 2027 (est.)

FT819 — Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)

IVA · Sep 2027 (est.)

IVA337 — NASH - Nonalcoholic Steatohepatitis

MAIA · Sep 2027 (est.)

6-Thio-2'-Deoxyguanosine — Carcinoma, Non-Small-Cell Lung

RNTX · Sep 2027 (est.)

LTI-03 — Idiopathic Pulmonary Fibrosis (IPF)

VNDA · Sep 2027 (est.)

Tradipitant — Motion Sickness

ACTU · Sep 2027 (est.)

ING-41 — Pancreatic Adenocarcinoma

Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).